Harambe’s beef is really with Redfield, not Kennedy, not Djokovic, not even you Parot. His former compadre evolved over time, is sharing his dissenting opinion, and Harambe is powerless to stop him or censor, nor can he call him an antivaxxer or a murderer.
“Vaccine Efficacy Duration
Well, and you have really some of the best science, as you described it.
[00:54:00]
I haven't seen that. But if you see it go, you drop it, it comes. But if you do that twice, it's pretty compelling evidence.
[Robert Redfield]
But I'll tell you, the vaccine doesn't last. Okay.
[Del Bigtree]
So the vaccine- Well, it's even, I mean, there's a lot of science showing it's even worse than that. It has a reverse efficacy.
[Robert Redfield]
There are some people, there's some data to suggest that it may even facilitate infection at some point. And there are viral systems that do that. We call it enhancing antibody. It's at a certain level. So I have this much antibody, it doesn't enhance. When I get this much antibody, because it has lots of little antibodies that do different things. And when you get to this level, it does enhance. So there is that possibility that some level of immunity actually makes you more susceptible to reinfection. So I'm not going to argue that that's impossible. I see it. If you look at flaviviruses and dengue, it's very operational. I happen to be vaccinated against COVID, so is my wife. We get vaccinated about every six months.
[00:55:02]
We don't use the mRNA vaccine. Because when I look at COVID and long COVID, which I have lots of patients now, I'm trying to understand what's making them sick. I think it's the spike protein, which is a special protein that the COVID virus has. And that protein has a very high affinity for a receptor in your body, which lines all your blood vessels and everywhere. And I think your body doesn't get rid of it very easy. It stays around a lot longer than Fauci used to try to tell people.
[Del Bigtree]
So... Well, I mean, we actually designed it to do that, right?
[Robert Redfield]
We inserted the pseudouridine. We made it so that it will last longer. It defies some sanity, I think. So it lasts longer. And without the recognition, but lasting longer means it can bind to our receptors and last longer on our receptors that cause problems. Right. All right. So now I know that. And now I have a vaccine that is the mRNA vaccine, and I use this vaccine, help develop it.
[00:56:08]
I don't use it anymore in my patients. And this is one of the things I can think could be relooked at about safety of the current vaccines 2025. That vaccine, when I give you an mRNA vaccine, I don't know how much mRNA you make. I turn your body into a factory, but I have no controls over that factory. I mean, you can make a lot, you can make a little, and you can make it for a week, you can make it for six months. And Fauci and others used to argue that it doesn't last. Well, no, we now know some of these patients are making spike protein three, six months later. So I've switched in my thing, and where I think there's a safer vaccine, where I use the protein vaccine. It's made by Novavax. So when I give you the COVID vaccine, I'm giving you dead protein. Your body's not turned into a factory.
[00:57:00]
I know what the decay curve is of that dead protein in your body. And I just think it's a safer way. So like my wife and I, the last two or three vaccines we've got are the Novavax protein vaccine. And that's what I give for my patients. That said, I don't think it's unreasonable to go re-examine the safety of what we know about these vaccines.
[Del Bigtree]
mRNA Vaccine Concerns
You have the opposite happening though. You have mRNA, you have new mRNA vaccines that are trying to run and stay safe based on the COVID vaccine, which has an emergency use authorization.
[Robert Redfield]
You just saw the Biden administration just gave Moderna over $176 million to make a bird flu vaccine that way. I'm not sure that technology is going to stand the test of time.
[Del Bigtree]
I agree. But I mean, there's a danger when you have a technology that we don't know a whole lot about. As you said, it seems ad hoc, willy-nilly. It's lasting in some people longer than others.
[Robert Redfield]
It's a fair debate that should be done transparently. I was on the Warp Speed board and we reviewed over 120 vaccines and we selected six, two vector vaccines, one was AstraZeneca, one was J&J, two mRNA vaccines, Moderna and Pfizer, and two protein vaccines, Novavax and a company that was GSK and Sophie Pasteur together.
[00:58:23]
Five of those six vaccines made it over the goal line. The J&J, I mean the GlaxoSmithKline, Sanofi didn't make it over the goal line. They had some issues in the way they designed the trial.
[Del Bigtree]
But there were some- I just think that it was the design of the trial and not necessarily the way you said that I find kind of funny.
[Robert Redfield]
Like if they had designed a better trial, well, they could have because I think they had trouble in the immunogenicity in older adults, which we know older adults have immunogenicity problems in general. And the way they designed it, they were over here.
[00:59:03]
[Del Bigtree]
But in a way, they should do it for older adults because that's the group that we're really trying- Well, I mean, look, when we look at the trials for Pfizer and Moderna, I mean, most of the high-risk groups aren't in the trial. Right.
[Robert Redfield]
And so GSK was more the way we would like to see it, okay? They put their high-risk groups in there. And they didn't get over the goal line because their immunogenicity was there. But let me- What I was going to say is when you- Debbie Birx and I were on the board and we voted for the protein vaccines to be included. And we didn't win. The committee accepted the two vector and the two mRNA. And part of the reason we didn't win is everyone didn't think it was sexy enough, all right? The mRNA was new, it was sexy.
[01:00:00]
[Del Bigtree]
The vector- Does the protein have the same ability? mRNA seems to be offering a real opportunity to vaccine makers in that, I mean, suddenly we can make a vaccine almost overnight. I mean, you just... Does the protein vaccine have the ability to ramp up as quickly?
[Robert Redfield]
It's a little longer. However, the reason Birx and I were big advocates of the protein vaccine, we both did vaccine research. He worked for me for a number of years in the army, is we saw that this was a vaccine that needed to go global. And the ability to manufacture protein vaccines was simple. It was straightforward. It was technology we've used for over 50 years. We know it works. And it's going to be cheap. And I could make a plan to make this vaccine in Nairobi or anywhere I want to. And you know that the mRNA vaccines have been trying to have a plan in Kenya and in South Africa, and they've all busted, right?
[01:01:00]
The mRNA vaccines, you need freezers at 100- What happened to the freezers? You need freezers 180 degrees, minus 80. My vaccine, you don't need it. You can put it in the back of your car. So I wanted the protein vaccines. We lost, largely because there was a pretty heavy bias by other people in the room that if it wasn't new, it couldn't be valuable. Birx and I felt this is 50-year technology, let's go with it. And so you raise a good point. At what point does new platform technology get widely positioned? Because for example, with the mRNA vaccines, there's issue about what I've talked about, prolonged production. We don't know if this mRNA gets somehow stabilized in mitochondria or somewhere in cytoplasm. There's also concerns that have been raised about other nucleic acid that may be in those vaccines that is active.
[01:02:02]”